• Text Resize A A A
  • Print Print
  • Share Share on facebook Share on twitter Share

Hepatitis Blog Archives

All | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

Ron Valdiserri
Urging all of us to recommit to achieving those life-saving national goals, he also identifies four important actions we all can take in the coming year to address remaining challenges and advance toward those goals.
Ron Valdiserri
2014 has been a year of both opportunities and challenges in the fight against viral hepatitis.
FDA logo
The U.S. Food and Drug Administration today approved Viekira Pak to treat patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with a type of advanced liver disease called cirrhosis.
Ron Valdiserri
Last month, the American Association for the Study of Liver Diseases (AASLD) annual meeting (The Liver Meeting®) took place, convening nearly 10,000 physicians, surgeons, researchers, allied health professionals and advocates from around the world to discuss the natural history, prevention, and cure of liver diseases.
Carl and Ron
Today, we share some of our blogs about efforts to enhance the treatment and care of those living with HIV in the U.S. so that individuals can stay healthy, live longer, and reduce the risk of transmission of the virus to others.
Elinore F. McCance-Katz, M.D., Ph.D.
Advancing the Viral Hepatitis Action Plan
On Tuesday, 10/14/14, the cross-government working group supporting and monitoring the implementation of the updated Viral Hepatitis Action Plan—the Viral Hepatitis Implementation Group or “VHIG”—met in Washington, DC to share updates on 2014 accomplishments and plans for the coming year.


  • of 6
  • >